Precision medicine for high-risk neuroblastoma

高危神经母细胞瘤的精准医学

• 批准号: nhmrc : 1146817
• 负责人: A/Pr Alexander Swarbrick
• 金额: $ 44.63万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/precision-medicine-high-risk-neuroblastoma/1320742
• 关键词: Precision; medicine; risk; neuroblastoma

Despite aggressive treatment, the survival rate for high-risk neuroblastoma patients is below 50%. We recently found that these poor-outcome neuroblastomas have a defect in a key drug response pathway, called the JNK pathway. Standard-of-care neuroblastoma drugs all require the JNK pathway to kill neuroblastoma cells, although we have now identified alternative drugs that do not require JNK. We now plan to demonstrate the efficacy of these drugs in neuroblastomas with a defective JNK pathway.

尽管采取积极治疗，高危神经母细胞瘤患者的生存率仍低于 50%。我们最近发现这些预后不良的神经母细胞瘤在一个关键的药物反应途径（称为 JNK 途径）中存在缺陷。标准护理神经母细胞瘤药物都需要 JNK 途径来杀死神经母细胞瘤细胞，尽管我们现在已经确定了不需要 JNK 的替代药物。我们现在计划证明这些药物在 JNK 通路缺陷的神经母细胞瘤中的疗效。